Results 51 to 60 of about 8,864 (209)

Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy [PDF]

, 2016
Background\ud \ud Radiation-induced nephropathy is still dose limiting in radionuclide therapy of neuroendocrine tumors. We investigated the nephroprotective potential of the angiotensine converting enzyme inhibiting drug enalpril after [177Lu]-DOTATATE ...
Julia Schlichtiger, Peter Bartenstein (457352), Schlichtiger, Julia, Hacker, Marcus, Tanja Herrler, Gildehaus, Franz J., Ilhan, Harun, Harun Ilhan (770030), Andrei Todica, Marcus Hacker (691196), Carmen Wängler (3765865), Paul Cumming (457453), Cumming, Paul, Wängler, Carmen, Franz J. Gildehaus, Paul Cumming, Marcus Hacker, Haug, Alexander Robert, Herrler, Tanja, Alexander Haug (3765856), Hao Wang, Alexander R. Haug, Harun Ilhan, Todica, Andrei, Carmen Wängler, Andrei Todica (3592217), Julia Schlichtiger (3765847), Peter Bartenstein, Haug, Alexander R., Tanja Herrler (641818), Franz Gildehaus (3765853), Wang, Hao, Bartenstein, Peter, Hao Wang (39217)   +33 more
core   +3 more sources

The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET

International Journal of Endocrinology, 2021
Purpose. The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs).
Anna Zemczak, Paweł Gut, Dariusz Pawlak, Maciej Kołodziej, Leszek Królicki, Beata Kos-Kudła, Marek Ruchała, Grzegorz Kamiński, Jolanta Kunikowska   +8 more
doaj   +1 more source

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, Volume 117, Issue 10, Page 2619-2635, October 2026.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE

Endocrine Connections, 2021
Background: Monitoring of pancreatic neuroendocrine tumors (PanNET) undergoing peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE depends on changes in tumor size, which often occur late.
Olof Joakim Pettersson, Katarzyna Fröss-Baron, Joakim Crona, Anders Sundin   +3 more
doaj   +1 more source

The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Somatostatin receptor 2 is expressed in nasopharyngeal carcinoma (NPC). We report genomic and transcriptomic analysis results of 163 NPC cases, demonstrating that somatostatin receptor 2 (SSTR2) gene expression in EBV‐positive and in EBV‐negative NPC correlated with genomic alterations and an inflamed microenvironment.
Dara Bracken‐Clarke, Elisabetta Xue, Harris Krause, Tolulope Adeyelu, Mark G. Evans, Dilara Akbulut, Martha Quezado, Nishant Gandhi, Alex Farrell, Heloisa P. Soares, Emil Lou, Minh Phan, Rusha Patel, Ari M. Vanderwalde, Andrew Elliott, Conor E. Steuer, Nabil F. Saba, Daniel J. Lubin, Nyall R. London Jr, James L. Gulley, Charalampos S. Floudas   +20 more
wiley   +1 more source

Different technical possibilities of post- -therapeutic tandem 90Y/ /177Lu-DOTATATE imaging [PDF]

, 2013
BACKGROUND: Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms derived from endocrine stem cells.These tumors are characterized by overexpression of somatostatinreceptors (SSTR), which is utilized for imaging using SSTR analogs.
Pawłowicz, Bożena, Królicki, Leszek, Czwarnowski, Piotr, Aksamit, Dariusz, Pawlak, Dariusz, Bajera, Adam, Kunikowska, Jolanta; Nuclear Medicine Department, Medical University of Warsaw, Poland, Sawicka, Magdalena   +7 more
core   +1 more source

Filters Effect on Image Quality of 177Lu-DOTATATE SPECT Images for Neuro-Endocrine Tumors Scanning

Frontiers in Biomedical Technologies
Purpose: The quality of the image in SPECT scans depends on the imaging parameters which are determined experimentally in the field of nuclear medicine.
Hussein Dakhil, Mohammad Reza Deevband, Mahasti Amoui, Ahmad Mostaar, Mahdi Ghorbani, Mohsen Khosroabadi, Mohammad Ali Ghodsirad   +6 more
doaj   +1 more source

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trialResearch in context

EClinicalMedicine
Summary: Background: In the phase 3 NETTER-2 study, first-line [177Lu]Lu-DOTA-TATE (hereafter 177Lu-DOTATATE) significantly improved progression-free survival in patients with advanced, well-differentiated, higher grade 2–3 (Ki67 ≥10% and ≤55 ...
Diego Ferone, Marianne Pavel, Ken Herrmann, Pamela L. Kunz, Sten Myrehaug, Daniel Halperin, Beth Chasen, Jaume Capdevila, Amparo García-Burillo, Salvatore Tafuto, Secondo Lastoria, Do-Youn Oh, Changhoon Yoo, Stephen Falk, Thorvardur R. Halfdanarson, Maddalena Sansovini, Laura Gerard, Emmanuel Deshayes, Angelina Filice, Ilya Folitar, Yufen Zhang, Wouter W. de Herder, Simron Singh   +22 more
doaj   +1 more source

Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE

EJNMMI Physics, 2022
Purpose Recent reports personalizing the administered activity (AA) of each cycle of peptide receptor radionuclide therapy based on the predicted absorbed dose (AD) to the kidneys (dose-limiting organ) have been promising.
Javian C. Malcolm, Nadia Falzone, Jennifer E. Gains, Matthew D. Aldridge, David Mirando, Boon Q. Lee, Mark N. Gaze, Katherine A. Vallis   +7 more
doaj   +1 more source